Total Live Articles: 463

Calcium Pyrophosphate Deposition Disease (CPPD) (Pseudogout)

EULAR recommendations for calcium pyrophosphate deposition. Part II: Management. Published: 2011.

Pseudogout

Note on terminology:

  • Calcium pyrophosphate deposition disease (CPPD) is the umbrella term for the condition where calcium pyrophosphate crystals form and deposit in joint tissues
  • Chondrocalcinosis refers to the physical finding of calcium pyrophosphate crystals in the hyaline or fibrocartilage (on X-ray)
  • Pseudogout refers to acute CPPD

Causes and Risk Factors

CPPD is characterised by the deposition of calcium pyrophosphate crystals within the joint, which then triggers an inflammatory immune response

Risk factors: [Ref]

  • Genetic factors (e.g. mutations in ANKH and ENPP1 genes)
  • Advanced age (30-50% of patients are >85 y/o)
  • Pre-existing osteoarthritis
  • Metabolic and endocrine conditions
    • Hypomagnesaemia
    • Hyperparathyroidism
    • Haemochromatosis

Clinical Features

There are 2 main clinical subtypes of CPPD: [Ref]

Clinical subtype Clinical features
Acute CPPD (pseudogout) Possible triggers include physical trauma and surgical procedures

Sudden onset of acute monoarticular / oligoarticular arthritis:

  • Severe hot, red, swollen joint pain – mimicking a gout attack
  • The severe joint pain can temporarily restrict movement and limit daily activities
  • Involved joint
    • Knee – most common
    • It also frequently affects the wrists and hips

Attacks are generally self-limiting, lasting 7-10 days

Chronic CPPD (pseudo-rheumatoid arthritis) Presents as chronic, symmetrical, and deforming polyarthritis

  • Patient may present with persistent joint inflammation or recurrent acute flares that mimic rheumatoid arthritis
  • Most commonly involves the wrists and metacarpal joints
  • Tenosynovitis is common and can lead to carpal tunnel syndrome or cubital tunnel syndrome

Investigation and Diagnosis

[Ref]

Imaging 1st line: X-ray

  • Typical finding: chondrocalcinosis
    • A thin, linear or punctate calcification within cartilage, often seen parallel to the articular surface
    • In the knee: calcification of the menisci or within the articular cartilage
    • In the wrist: calcification of the triangular fibrocartilage complex
  • However, X-rays only have a ~40% sensitivity for detecting clinically significant CPPD
Synovial fluid analysis Joint aspiration for synovial fluid analysis is the gold standard test

  • Appearance: cloudy, yellow
  • Viscosity: reduced
  • WBC count and differential: 2,000 – 50,000 cells/µL with polymorph (neutrophil) predominance
  • Microscopy: rhomboid-shaped calcium pyrophosphate crystals with weak positive birefringence
  • Gram stain / culture: -ve
  • Glucose: normal

Synovial fluid microscopy in crystal arthropathy

  • Gout (monosodium urate crystals): needle-shaped crystals with negative birefringence
  • Pseudogout (calcium pyrophosphate crystals): rhomboid-shaped with positive birefringence (pseudogout = positive)
Blood tests Since CPPD can be triggered by underlying metabolic conditions, a metabolic panel is recommended:

  • Calcium, magnesium and phosphate levels
  • Iron studies (to screen for haemochromatosis – esp. in younger patients)
  • TSH and PTH levels
  • Serum urate levels (to exclude gout)

Management

There are currently no approved disease-modifying therapies to stop or reverse the deposition of calcium pyrophosphate crystals.

Clinical subtype Management
Acute CPPD (pseudogout) Initial management: local treatment (esp. for monoarticular or oligoarticular attacks)

  • Apply ice
  • Rest the joint
  • Joint aspiration + intra-articular corticosteroid injection

Local treatment is typically sufficient to resolve the flare. If ineffective, consider systemic treatment:

  • 1st line: oral NSAIDs or low-dose colchicine
  • 2nd line: corticosteroids (oral / IM / IV) or ACTH injection
Chronic CPPD
  • 1st line: oral NSAIDs and/or low-dose colchicine
  • 2nd line: low-dose oral corticosteroids
  • 3rd line: methotrexate
  • 4th line: hydroxychloroquine

References

Share Your Feedback Below

Disclaimer

We’re actively expanding Guideline Genius to cover the full UKMLA content map. Therefore, you may notice some conditions not uploaded yet, or articles that currently focus on diagnosis and management for now.

We are also continuously reviewing and updating existing content to ensure accuracy and alignment with current guidelines. Some earlier articles are undergoing revision as part of this process. Once all content has been fully reviewed, this will be clearly communicated on the platform.

For updates, follow us on Instagram @guidelinegenius.

We welcome any feedback or suggestions via the anonymous feedback box at the bottom of each article and will do our best to respond promptly.

Thank you for your support.
The Guideline Genius Team

UK medical guidelines made easy. From guidelines to genius in minutes!

Quick Links

Cookie Policy

Social Media

© 2026 GUIDELINE GENIUS LTD

Stay Updated withGuideline Genius

Sign up to be notified when our newsletter launches, covering major guideline updates, article updates, and future UKMLA resources.